Newcastle startup Invenirex closed a £2 million seed round to commercialize an enzyme‑free nucleic acid detection platform built around programmable DNA microstructures dubbed 'nanites.' The firm’s Rosalind system performs isothermal capture and digital readout, claiming absolute quantification with sensitivity improvements versus qPCR and a 45‑minute time to result. The company plans a research‑use launch and is advancing toward clinical in‑vitro diagnostic validation. Invenirex’s technology avoids enzymatic amplification by using paired nanite probes distributed into microchips with millions of picowells for single‑molecule readouts. The startup is pursuing initial clinical use cases in oncology and sepsis and is developing high‑throughput instruments for vaccine-development support. The seed round includes institutional venture capital and Innovate UK grant funding. The financing highlights continued investor interest in rapid, sensitive diagnostics that de‑risk supply‑chain and enzyme‑dependence constraints; developers and diagnostic labs should track ongoing validation data and regulatory submissions as Invenirex moves from RUO toward clinical applications.